New QNASL Spray Strength Now Available for Pediatric Use Teva announced the launch of QNASL (beclomethasone dipropionate) Nasal Aerosol in a new 40mcg strength. Teva announced the launch of QNASL ...

Teva announced data from the Phase 3 clinical program for QNASL (beclomethasone dipropionate) Nasal Aerosol, highlighting the drug’s efficacy profile in treating children (ages 6–11) with nasal ...

Phase III Data for Teva's QNASL ® (beclomethasone dipropionate) Demonstrate Efficacy Profile in Pediatric Patients with Seasonal Allergic Rhinitis Additional Phase III Data Show Long-Term Ocular ...

First Waterless Nasal Allergy Spray Approved for Children as Young as Four Years of Age JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVJF), (NYSE:TEVA) announced today that the U ...

JERUSALEM, Israel, November 6, 2012 – Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL® (beclomethasone dipropionate) Nasal ...

Teva Pharmaceutical Industries announced that the FDA has approved QNASL Nasal Aerosol, a new, “dry” nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in ...

Data to be Presented Regarding Impact on Sleep Quality and Nasal Symptom Relief at 24 Hours Post Dose in Patients with Seasonal and Perennial Allergic Rhinitis Data will be presented at the meeting ...

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that data from four late-stage studies examining QNASL™ (beclomethasone dipropionate [BDP]) HFA, a nasal ...

Teva just got the OK for a new entry in the $2.5 billion market for nasal allergies aerosols. The Food and Drug Administration approved Teva’s QNASL, which the company (NASDAQ:TEVA) said is a “dry,” ...

In this pharmacy news, Qnasl is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhinitis in patients 12 years of age and older.

Additional Phase III Data Show Long-Term Ocular Safety Profile and Support Device Functionality and Reliability "QNASL is a much-needed treatment option for the millions of adults and adolescents ...